ED-B fibronectin as a target for antibody-based cancer treatments

Bibliography

• HELDIN CH, RUBIN K, PIETRAS K, OESTMAN A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev Cancer (2004) 4:806–813.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the mechanismof interstitial fluid pressure and its impact on cancer therapy.
   Google Scholar
• JAIN RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Delivery (1997) 26:71–90.
   PubMed Web of Science ®Google Scholar
• DEWHIRST MW, TSO CY, OLIVER R et al.: Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int. J. Radiat. Oncol Biol. Phys. (1989) 17:91–99.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 6:559–593.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: The role of angiogenesis in tumor growth. Sem. Cancer Biol. (1992) 3:65–71.
   PubMedGoogle Scholar
• HUANG X, MOLEMA G, KING S et al: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (1997) 275:547–550.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of proof of principleof antibody-mediated vascular targeting.
   Google Scholar
• POTTS JR, CAMPBELL ID: Fibronectin structure and assembly. Curl: Opin. Cell Biol. (1994) 6:648–655.
   PubMed Web of Science ®Google Scholar
• GEORGE EL, GEORGES-LABOUESSE EN, PATEL-KING RS et al: Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development (1993) 119:1079–1091.
   PubMed Web of Science ®Google Scholar
• •Genetic proof for the importance of flbronectin for embryonic development.
   Google Scholar
• GEORGE EL, BALDWIN HS, HYNES RO: Fibronectins are essential for heart and blood vessel morphogenesis but are dispnesable for for initial specification of precursor cells. Blood (1997) 90:3073–3081.
   PubMedGoogle Scholar
• ZARDI L, CARNEMOLLA B, SIRI A et al.: Transformed human cells produce a new fibronectin isoform by alternative splicing of a previously unobserved exon. EMBO J. (1987) 6:2337–2342.
   PubMed Web of Science ®Google Scholar
• ••Discovery of ED-B-flbronectin.
   Google Scholar
• BERNDT A, BORSI L, XINMEI L et al:Evidence of ED-B+ fibronectin synthesis in humn tissues by non-radioactive RNA in situ hybridization. Investigation on carcinoma (oral squamous cell and breast cancer), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupytren). Histochem. Cell Biol. (1998) 109:249–255.
   Google Scholar
• PUJUGUET P, HAMMANN A, MOUTET M et al.: Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am. J. Pathol. (1996) 148:579–592.
   Google Scholar
• MID ULLA M, VERMA R, PIGNATELLI M et al.: Source of oncofetal ED-B-con-taming fibronectin: implication of production by both tumor and endothelial cells. Cancer Res. (2000) 60:164–169.
   PubMedGoogle Scholar
• DE CANDIA LM, ROGERS RJ. Characterization of the expression of the alterna-tive splicing of the ED-A, ED-B, and V-regions of fibronectin mRNA in bovine ovarian follicles and corpora lutea. Reprod. Feral. Dev. (1999) 11:367–377.
   PubMedGoogle Scholar
• DAHSE OK, ALT V, ZARDI I et al: Expression of EDA+ and EDB+ fibronectin splice variants in bone. Bone. (2004) 35:1334–1345.
   PubMedGoogle Scholar
• FFRENCH-CONSTANT C, VAN DE WATER L, DVORAK HF et al.: Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. I Cell Biol. (1989) 109:903–914.
   Google Scholar
• CASTELLANI P, VIALE G, DORCARATTO A et al: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. bit .j Cancer (1994) 59:612–618.
   PubMed Web of Science ®Google Scholar
• BIRCHLER M, VITI F, ZARDI L et al Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage derived human antibody fragment. Nat. Biotechnol (1999) 17:984–988.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating the suitability of theED-B-domain for the antibody-mediated targeted delivery of therapeutically active compounds.
   Google Scholar
• NICOLO M, BIRO A, CARDILLO-PICCOLINO F et al. Expression of extradomain-B-containing fibronectin in subretinal choriodal neovascular membranes. Am. J. Ophthalmol (2003) 135:7–13.
   PubMedGoogle Scholar
• MATTER CM, SCHULER PK, ALESSI P et al. Molecular imaging of atheroscle-rotic plaques using a human antibody against the extra-domain B of fibronectin. Circ. Res. (2004) 95:1223–1233.
   Google Scholar
• DUBIN D, PETERS HJ, BROWN LF et al. Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1958–1967.
   PubMed Web of Science ®Google Scholar
• KRIEGSMANN J, BERNDT A, HANSEN T et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of pa-tients with rheumatoid arthritis and osteoarthritis. Rheumatol Int. (2004) 24:25–33.
   PubMed Web of Science ®Google Scholar
• KACZMAREK J, CASTELLANI P, NICOLO G et al Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer (1994) 59:11–16.
   PubMed Web of Science ®Google Scholar
• D'OVIDIO M, MASTRACCHIO A, MARZULLO A et al.: Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carci-noma. Eur. J. Cancer. (1998) 34:1081–1085.
   Google Scholar
• SANTIMARIA M, MOSCATELLI G, VIALE GL et al.: Immunoscintigraphic detec-tion of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. (2003) 9:571–579.
   PubMed Web of Science ®Google Scholar
• ••First report showing the specificaccumulation of the high-affmity scFy L19 at the tumour site in patients.
   Google Scholar
• MENRAD A, ROSEWICZ S, WAGNER K et al.: Therapeutic efficacy of the recom-binant fusion protein L19-1L2 in orthotopic animal models for pancreatic-and hepatocellular carcinoma. The 21st International Conference of Advances in the Application of Monoclonal Antibodies in Clinical Oncology, June 28–30 (2004) Proceedings Suppl. p.15.
   Google Scholar
• KOSMEHL H, BERNDT A, STRASSBURGER S et al. Distribution of laminin and fibronectin isoforms in oral squamous cell carcinoma. BE J. Cancer. (1999) 81:1071–1079.
   Google Scholar
• MHAWECH P, DULGUEROV P, ASSALY M et al. ED-B fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncology (2005) 41:82–88.
   PubMed Web of Science ®Google Scholar
• KARELINA TV, EISEN AZ. Interstitial collagenase and the ED-B oncofetal domain of fibronectin as markers of angiogenesis in human skin tumors. Cancer Detect. Prey (1998) 22:438–444.
   PubMedGoogle Scholar
• CASTELLANI P, DORCARATTO A, PAU A et al.: The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningeomas. Act. Neurochir (Wien). (2000) 142:277–282.
   PubMedGoogle Scholar
• OHNISHI T, HIRAGA S, IZUMOTO S et al.: Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin. Exp. Metastasis (1998) 16:729–41.
   PubMed Web of Science ®Google Scholar
• CASTELLANI P, BORSI L, CARMENOLLA, B et al: Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Path. (2002) 161:1695–1700.
   PubMedGoogle Scholar
• EBBINGHAUS C, SCHEUERMANN J, NERI D et al.: Diagnostic and therapeutic application of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curt: Pharm. Des. (2004) 10:1537–1549.
   PubMed Web of Science ®Google Scholar
• FUKUDA T, YOSHIDA N, KATAOKA Y et al: Mice lacking the EDB segment of fi-bronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. (2002) 62:5603–5610.
   PubMedGoogle Scholar
• ••First report on the in vivo ED-Bknockout and a potential function of ED-B fibronectin.
   Google Scholar
• ASTROF S, CROWLEY D, GEORGE EL et al: Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mal Cell. Biol. (2004) 24:8662–8670.
   Google Scholar
• •Demonstration that the absence of ED-B fibronectin is not essential in a mouse model for angiogenesis.
   Google Scholar
• MENRAD A, CAO YJ, REDLITZ A et al: ED-B fibronectin as a target for antibody based therapeutics and the evaluation of phage angiomics for target identification and validation. Strategic Research Institute Conference on Vascular Targeting Agents (2004) November 08–09, Proceedings Suppl. p.l.
   Google Scholar
• MENRAD A, Cao YJ, REDLITZ A et al: Molecular and functional characterization of ED-B fibronectin selective function blocking antibodies and the evaluation of phage angiomics for target identification and validation. Human Antibodies (2004) 13:33.
   Google Scholar
• CASTELLANI P, SIRI A, ROSELLINI Cet al: Transformed human cells release different fibronectin variants than do normal cells. .1 Cell Biol. (1986) 103:1671–1677.
   PubMed Web of Science ®Google Scholar
• BORSI L, CARNEMOLLA B, CASTELLANI P et al: Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternatively splicing of mRNA pre-cursors in normal and transformed human cells. J. Cell Biol. (1987) 104: 595–600.
   PubMed Web of Science ®Google Scholar
• CARNEMOLLA B, BALZA E, SIRI A et al. A tumor-associated fibronectin isoform generated by alternatively splicing of messenger RNA precursors. J. Cell Biol. (1989) 108:1139–1148.
   PubMed Web of Science ®Google Scholar
• ALESSANDRI G, CHIRIVI RG, CATELLANI P et al.: Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab. Invest. (1998) 78:127–128.
   PubMed Web of Science ®Google Scholar
• ALESSANDRI G, CHIRIVI RG, FIORENTINI S et al: Phenotypic and functional characterization of tumor-derived microvascular endothelal cells. Glib. Exp. Metastasis (1999) 17:655–662.
   PubMedGoogle Scholar
• ALLPORT JR and WEISSLEDER R: Murine Lewis Lung Carcinoma-derived en-dothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro. Neoplasia (2003) 5:205–217.
   PubMed Web of Science ®Google Scholar
• CHIRIVI RG, PUENTE S, STORGARD CM et al: Angiogenesis induced by alter-natively spliced oncofetal fibronectin binding to endothelila cell integrin a301.AACR 92nd Annual Meeting March 24–28 (2001) Proceedings Suppl. 841B60.
   Google Scholar
• CARNEMOLLA B, LEPRINI A, ALLEMANNI G et al: The inclusion of the Type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. (1992) 267:24689–24692.
   PubMed Web of Science ®Google Scholar
• •The report describes that the mouse monoclonal antibody BC1 does not directly interact with the ED-B-domain.
   Google Scholar
• MARIANI G, LASKU A, PAU A et al.: A pilot pharmacokinetik and immunoszin-tigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer (1997) 80(12 Suppl.):2484–2489.
   Google Scholar
• ••First report showing the suitability of ED-B-fibronectin as a target structure for antibody-based therapies in humans.
   Google Scholar
• PINT A, VITI F, SANTUCCI A et al: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. (1998) 273:21769–21776.
   Google Scholar
• VITI F, TARLI L, GIOVANNONI L et al Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. (1999) 59:347–352.
   PubMed Web of Science ®Google Scholar
• CARNEMOLLA B, BORSI L, BALZA E et al: Enhancement of the antitumor prop-erties of interleukin-2 by its trageted delivery to the tumor blood vessel extracel-lular matrix. Blood (2002) 99: 1659-1665.
   Google Scholar
• HALIN C, RONDINI S, NILSSON F et al: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol (2002) 20:264–269.
   PubMed Web of Science ®Google Scholar
• LIENARD D, EWALENKO P, DELMOTTE JJ et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Chit. Oncol (1992) 10:52–60.
   PubMed Web of Science ®Google Scholar
• EGGERMONT AM, SCHAFFRODT-KOOPS H, LIENARD D et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with inter-feron-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Chit. Oncol (1996) 14:2653–2665.
   PubMed Web of Science ®Google Scholar
• BORSI L, BALZA E, CARNEMOLLA B et al: Selective targeted delivery of TNFa to tumor blood vessels. Blood (2003) 102:4384–4392.
   PubMed Web of Science ®Google Scholar
• RAN S, GAO B, DUFFY S et al: Infarction of solid Hodgkin's tumors in mice ny antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. (1998) 58:4646–4653.
   PubMed Web of Science ®Google Scholar
• NILSSON F, KOSMEHL H, ZARDI L et al.: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. (2001) 61:711–716.
   PubMed Web of Science ®Google Scholar
• •Demonstration that TF is therapeutically active after targeting to an abluminally oriented antigen.
   Google Scholar
• MARTY C, SCHEIDEGGER P, BALLMER-HOFER, K et al: Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expr. PuriE (2001) 21:156–164.
   PubMed Web of Science ®Google Scholar
• MARTY C, ODERMATT H, SCHOTT H et al: Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFV antibody modified liposomes. Br. .1 Cancer. (2002) 87:106–112.
   PubMed Web of Science ®Google Scholar
• MARTY C, SCHWENDENER RA: Cytotoxic tumor targeting with scFv anti-body-modified liposomes. Methods Mol. Med. (2005) 109:389–402.
   PubMedGoogle Scholar